Objectives -To evaluate the evidence for and against routine testicular cancer screening by prim.ary health care providers and patients (testicular self examination). Setting -Low reported frequency of routine screening for testicular cancer attributed to poor knowledge of the disease and how to screen for it. Methods -Literature based evaluation of the screening suitability of testicular cancer as a disease and palpation of the testis as the proposed screening test, and of the effectiveness of screening for testicular cancer.
To detect testicular cancer early, an increase in case finding and routine screening by patients and primary health care professionals is often recommended, for example by cancer groups. 12 However, the evidence base for this suggestion is unstated and there is no consensus over the desirability of routine screening for the disease.
The Canadian Task Force? and the United States Preventive Services Task Force" have reported that there is insufficient evidence to recommend for or against routine screening for testicular cancer. In the United Kingdom, national guidelines on testicular cancer screening have not been developed. Nevertheless, the Imperial Cancer Research Fund has produced a patient information leaflet, with funding from the Department of Health, recommending testicular self examination. 5 The leaflet also states that orchidopexy before the age of 10 and regular exercise may help to prevent testicular cancer. In fact, no consistently clear relationship between these factors and testicular cancer risk has been reported.
This article discusses the limited evidence available to inform the debate on whether users and providers of primary medical care should screen for testicular cancer. I consider three critical questions: How suitable for screening is testicular cancer as a disease? How suitable is palpation of the testes as the proposed screening test? How effective would screening be for testicular cancer? The result is a preliminary exploration of issues relevant to an evaluation of testicular cancer screening.
Screening suitability of testicular cancer To be suitable for screening a disease must be an important public health problem, be recognisable at an early stage in a high proportion of the screened population, and be amenable to a treatment that can significantly improve survival rates in those who have the disease at an early rather than a late stage." 7 Testicular cancer does not meet the first criterion." In many populations it is the most common cancer among men aged 20 to 34, but at these ages all cancers are rare." During 1983-87 the average annual incidence rate of testicular cancer per 100000 population (age standardised to the 1982 world standard population) was 3·7 in England and Wales.
10 Incidence rates of testicular cancer have been rising slowly in many white populations for at least 30 years," whereas rates of mortality from the disease have fallen during the past two decades. 11 Treatments, including orchidectomy, lymph node dissection, and chemotherapy, have unpleasant and serious side effects." However, the disease, to which about 120 annual deaths in England and Wales are now attributed, does not represent a major public health problem" and cannot justify the costs of screening all young men for the disease. " Signs of testicular cancer are usually detectable before symptom onset. The sign most easily detected is a palpable testicular mass within the substance of the testis itself. Ultrasound can help to differentiate between testicular tumours and other masses." Carcinoma in situ of the testis, which has been reported to be the precursor lesion of almost all testicular tumours, 1415 also seems to produce an irregular echopattern on ultrasound examination. 16 Definitive confirmation of the disease requires surgical biopsy and pathological examination of tissue.
Testicular cancer is highly curable. Radiation, surgery, chemotherapy, or a combination of these treatments is given according to the clinical stage and type of the tumour. Owing particularly to the addition of cisplatin to chemotherapy regimens in the late 1970s, five year survival rates with the disease exceed 90% when it is localised or regional." For patients with metastatic disease, however, cure rates are as low as 44%. 17 To reduce morbidity and mortality rates, screening would need to result in the earlier detection and treatment of late stage disease. There is no evidence of fulfilment of this criterion for testicular cancer.i "
Screening tests
Palpation of the testis, whether by patients or, after a carefully performed history, by health care professionals, is the proposed screening test for testicular tumours. Easy and cheap to administer, it involves a minimum of discomfort and is safe. Prima facie it has a low monetary cost to the health service but any diagnostic follow up is expensive and there are the opportunity costs associated with foregoing other activities. To be suitable as a screening test, palpation must yield valid (that is, accurate) results about the likelihood of the testicular cancer being present in individuals and be acceptable to health care providers and users.
Estimates of the sensitivity and specificity of palpation as a screening test for testicular cancer are based on non-experimental evidence. Sensitivity is the likelihood of a positive test result in men with the disease. In practice, high sensitivity depends on a small proportion of false negative results. The sensitivity of palpation of the testes as a screening test for testicular cancer seems to be high. A suspicious testicular mass has been reported to be palpable in 97% of men with testicular cancer," and Kromann-Andersen et ai" reported that "both clinical and ultrasonographic examinations had high sensitivity (90%) in detecting testicular cancer".
Any abnormal scrotal mass within the substance of the testis should be considered malignant until proved otherwise. 1321 However, detection of such a mass does not preclude delays in seeking medical attention or even in diagnosis and initiation of appropriate treatment. Though typically aware of the abnormality in the testis,B patients may delay seeking medical attention because of their lack of awareness ofthe potential dangers or because of fear or ernbarrassment.P:" In addition, health care professionals have "misdiagnosed" testicular tumours as infection, trauma, hydrocele, and other benign conditions. 2526 In two studies 272B almost one third of the patients with testicular tumours experienced delays of two months or longer between initial presentation to a medical practitioner and the start of suitable treatment.
Specificity is the likelihood of a negative test result among those who do not have the disease. Palpation is likely to detect any suspicious mass but though testicular tumours are rare, benign conditions can mimic therri": thus, in a prospective study in Denmark, clinical examination erroneously indicated testicular cancer in 18 of 94 consecutive patients who did Buetow not have this disease but were operated on for scrotal disorders." The specificity of palpation (81 %) as a screening test was thus associated with significant, unnecessary costs. In the late 1970s an attempt was made to reduce the screening significance of false positive results and increase test specificity at the cost of reduced sensitivity.I " Now, the importance of detecting cancer early is generally regarded as being so important as to justify emphasising sensitivity over specificity. 30 The
The acceptability of palpation as a screening test for testicular cancer depends on the knowledge of, and attitudes towards, the disease and the screening test among patients and health care professionals. Young adult men are underrepresented in general practice and do not regularly use other medical services. 12 Low acceptance rates by women of breast self examination" suggest that testicular self examination would fare no better as a screening device. This seems likely because breast cancer has a much higher incidence than testicular cancer and women are more likely than men to know about and value self examination practices for cancer detection." . Most studies of testicular self examination have been undertaken in the United States where, over the past 13 years, the self reported prevalence of routine performance of the procedure has usually ranged from 4 % to 8 %.223435 These results are consistent with those of a large study of the attitudes and practices towards testicular self examination of university students taking non-health courses in 21 European countries during 1988-90. 36 Of the 7304 men in this study, all aged 17 to 30, 3% reported monthly testicular self examination; 10% occasional examination and 87% having never practised testicular self examination. There were large differences in these proportions across the European samples, but the denominators were not published. Rates of monthly testicular self examination ranged from 8·1 % in West Germany to 0% in Iceland. They were 1·7% in Scotland, 3·8% in England, and 4·8% in Ireland." By comparison, Thornhill et aP7 had reported that 1% of 395 well educated Irish men performed testicular self examination regularly.
Low levels of reported testicular self examination continue to be attributed to a lack of knowledge by young men about the procedurev " and testicular cancer. 232433 An alternative explanation is that scientific evidence has failed to show any net benefit of routine testicular self examination. Some patients have not perceived its benefits to outweigh the burden."
Little is known about the attitudes of health care professionals to screening for testicular cancer. Two thirds of 83 general practitioners in Tasmania, Australia, reported that they should screen asymptomatic patients for the disease but only 21 (25%) said they did SO.39 By comparison, 49% of 116 primary care physicians in South Carolina reported routine, age appropriate testicular examinations of patients. Whereas 28% of these physicians reported routinely teaching male patients testicular self examination.t? only 21 of the general practitioners in Tasmania claimed to do so, though 57 stated they should." The low priority accorded by these health care professionals to educating and screening patients for testicular cancer may be due to uncertainty about the cost effectiveness of doing so, time constraints, and, among patients, social inhibitions.
Screening effectiveness
If screening were undertaken, its short term effectiveness would depend on operational measures including the size of the screened population, the frequency of the screening; monetary costs, and the positive predictive value. The low prevalence of testicular cancer makes routine screening of all young men cost ineffective. The United States Preventive Services Task Force has thus recommended that only men with a history of cryptorchidism, orchidopexy, or testicular atrophy be periodically screened for testicular cancer," The positive predictive value measures the prevalence of actual disease among subjects with a positive screening test result. The positive predictive value for testicular cancer is low with palpation of the testes because this test seems to have low specificity and, except in select subgroups, the prevalence rate of testicular cancer is low. In the study by KrommanAndersen et al/ o clinical examination and ultrasonography yielded positive predictive values for detection of testicular cancer of 33% and 53% respectively.
The long term effectiveness oftesticular cancer screening is unknown and would depend on the detection of earlier stage tumours and reductions in the case fatality rate and site specific cancer mortality rate. Because metastasis can occur when the primary tumours are still small (metastases by non-palpable testicular tumours are extremely rare),1841 there may be gains from screening high risk men. However, it has not been shown that screening even this group for testicular cancer influences delay at diagnosis and reduces mortality and morbidity. 8
Conclusion
A growing number of published reports lament both the lack of education of patients and the medical community about the signs and symptoms of testicular cancer and the low, reported frequency of routine screening for the disease by health care professionals and young men. This latter concern is unsupported by a demonstration of evidence. Based on the 5 literature available, this article has identified and discussed the most important issues relevant to an evaluation of testicular cancer screening.
As a disease, testicular cancer is not suitable for screening. Its low prevalence (notwithstanding increases in incidence in most white populations) does not constitute a significant public health problem and would produce a high financial cost for each case detected through routine screening by health care professionals. As a screening test, palpation of the testis has high sensitivity for tumour detection but levels of specificity and positive predictive value seem to be low, which can lead to unnecessary patient anxiety and inefficient use of scarce resources. The lack of scientific evidence, rather than ignorance of it, seems best to explain the low reported levels of testicular self examination and professional screening for testicular cancer.
I suggest that testicular palpation and advice on testicular self examination should not be offered routinely and unsolicited by health care providers to patients. It is uncertain that screening by either group sufficiently alters the stage at which testicular tumours are detected to improve the patient's prognosis. It is also inadvisable, therefore, for health care professionals only to screen the patients most at risk of the disease. If asked, these providers should tell patients that testicular cancer is a rare disease, even in young men, and palpation may lead to its earlier detection but increase the risk offalse positive findings. Routine testicular cancer screening by patients and health care professionals is not justified by the evidence available. 
